Unum Therapeutics Inc (NASDAQ:UMRX) – Equities researchers at Wedbush upped their Q3 2020 earnings per share estimates for shares of Unum Therapeutics in a research report issued to clients and investors on Wednesday, July 8th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.03) for the quarter, up from their previous estimate of ($0.04). Wedbush currently has a “Outperform” rating and a $4.00 target price on the stock. Wedbush also issued estimates for Unum Therapeutics’ Q4 2020 earnings at ($0.03) EPS, FY2020 earnings at ($0.47) EPS, Q1 2021 earnings at ($0.03) EPS, Q2 2021 earnings at ($0.04) EPS, Q3 2021 earnings at ($0.05) EPS, Q4 2021 earnings at ($0.06) EPS, FY2021 earnings at ($0.18) EPS, FY2022 earnings at ($0.30) EPS, FY2023 earnings at ($0.35) EPS and FY2024 earnings at ($0.35) EPS.

Unum Therapeutics (NASDAQ:UMRX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. The firm had revenue of $7.03 million during the quarter, compared to analyst estimates of $3.00 million. Unum Therapeutics had a negative net margin of 99.09% and a negative return on equity of 83.39%.

Several other research analysts have also commented on the stock. Zacks Investment Research upgraded shares of Unum Therapeutics from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research note on Saturday, May 30th. HC Wainwright dropped their target price on shares of Unum Therapeutics from $18.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, March 27th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $2.88.

NASDAQ UMRX opened at $3.28 on Monday. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.16. The firm has a market cap of $103.46 million, a PE ratio of -3.81 and a beta of 1.32. The company has a 50 day moving average price of $0.86 and a 200 day moving average price of $0.67. Unum Therapeutics has a 52 week low of $0.29 and a 52 week high of $3.72.

An institutional investor recently raised its position in Unum Therapeutics stock. Renaissance Technologies LLC grew its holdings in Unum Therapeutics Inc (NASDAQ:UMRX) by 2,626.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 354,458 shares of the company’s stock after acquiring an additional 341,458 shares during the period. Renaissance Technologies LLC owned about 1.16% of Unum Therapeutics worth $255,000 at the end of the most recent quarter. 29.19% of the stock is owned by institutional investors.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a biopharmaceutical company, develops and commercializes immunotherapy products for cancer. The company is developing ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (r/r NHL).

Featured Article: Marijuana Stocks Future Looks Bright

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.